Venlafaxine-induced encephalopathy in term newborn

Abstract

The use of venlafaxine, a selective serotonin and norepinephrine reuptake inhibitor, for the management of depression in women of childbearing age has been on the rise, and there have been multiple case reports in the literature tying venlafaxine in-utero exposure to a form of neonatal encephalopathy presenting as neonatal abstinence syndrome. We present the case of a 5-day-old term infant whose mother was on venlafaxine throughout her pregnancy and presented with hypothermia, poor feeding, and decreased activity level. She subsequently had a negative sepsis workup and required nasogastric tube feedings for 2 weeks with spontaneous recovery and no clinical sequelae post-discharge. This case highlights the non-trivial potential risk of venlafaxine withdrawal in exposed newborns and the need for close observation. We propose a management framework for such situations in affected infants.

Role of JNK in the Regulation of Xenobiotic Metabolizing Function of Hepatocytes

“…This psychotropic pharmaceutical (presented by a racemate of R-and S-enantiomers) is one of the most effective modern antidepressants; its therapeutic effect is realized via blockade of serotonin, norepinephrine, and dopamine reuptake [9]. However, its low efficiency in some cases [3,5,6] requires the development of personalized approaches to venlafaxine therapy, including modification of its pharmacokinetics and pharmacodynamics [1].…”